Open AccessModern aspects of antiangiogenic therapy in ovarian cancer
Author(s) -
А. А. Румянцев,
Ilya Pokataev,
С. А. Тюляндин
Publication year - 2018
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2018-19-17-21
Subject(s) - bevacizumab , ovarian cancer , antiangiogenic therapy , medicine , angiogenesis , disease , oncology , cancer , drug , cancer therapy , cancer research , chemotherapy , pharmacology
The process of angiogenesis is essential for the growth and spread of malignant tumours. Antiangiogenic therapy is deeply embedded in the standard treatment of disseminated ovarian cancer (OC). The numerous studies have demonstrated its efficacy in various stages of the therapy of this disease; bevacizumab is the best-investigated anti-angiogenic drug for OC. This article presents a review and analysis of the most significant studies of the efficacy of anti-angiogenic therapy in ovarian cancer, and describes various aspects of its use in this disease.